Drug Consumption in 2017 - 2020

Drug Consumption in 2017 - 2020

Page 1 Drug consumption in 2017 - 2020 2020 2019 2018 2017 DDD/ DDD/ DDD/ DDD/ 1000 inhab./ Hospital 1000 inhab./ Hospital 1000 inhab./ Hospital 1000 inhab./ Hospital ATC code Subgroup or chemical substance day % day % day % day % A ALIMENTARY TRACT AND METABOLISM 322,79 3 312,53 4 303,08 4 298,95 4 A01 STOMATOLOGICAL PREPARATIONS 14,28 4 12,82 4 10,77 6 10,46 7 A01A STOMATOLOGICAL PREPARATIONS 14,28 4 12,82 4 10,77 6 10,46 7 A01AA Caries prophylactic agents 11,90 3 10,48 4 8,42 5 8,45 7 A01AA01 sodium fluoride 11,90 3 10,48 4 8,42 5 8,45 7 A01AA03 olaflur 0,00 - 0,00 - 0,00 - 0,00 - A01AB Antiinfectives for local oral treatment 2,36 8 2,31 7 2,31 7 2,02 7 A01AB03 chlorhexidine 2,02 6 2,10 7 2,09 7 1,78 7 A01AB11 various 0,33 21 0,21 0 0,22 0 0,24 0 A01AD Other agents for local oral treatment 0,02 0 0,03 0 0,04 0 - - A01AD02 benzydamine 0,02 0 0,03 0 0,04 0 - - A02 DRUGS FOR ACID RELATED DISORDERS 73,05 3 71,13 3 69,32 3 68,35 3 A02A ANTACIDS 2,23 1 2,22 1 2,20 1 2,30 1 A02AA Magnesium compounds 0,07 22 0,07 22 0,08 22 0,10 19 A02AA04 magnesium hydroxide 0,07 22 0,07 22 0,08 22 0,10 19 A02AD Combinations and complexes of aluminium, 2,17 0 2,15 0 2,12 0 2,20 0 calcium and magnesium compounds A02AD01 ordinary salt combinations 2,17 0 2,15 0 2,12 0 2,20 0 A02B DRUGS FOR PEPTIC ULCER AND 70,82 3 68,91 3 67,12 3 66,05 4 GASTRO-OESOPHAGEAL REFLUX DISEASE (GORD) A02BA H2-receptor antagonists 0,17 7 0,74 4 1,10 4 1,11 5 A02BA02 ranitidine 0,00 1 0,63 3 0,99 3 0,99 4 A02BA03 famotidine 0,16 7 0,11 8 0,11 10 0,12 9 A02BB Prostaglandins 0,04 62 0,03 73 0,03 72 0,03 73 A02BB01 misoprostol 0,04 62 0,03 73 0,03 72 0,03 73 A02BC Proton pump inhibitors 69,26 3 66,90 3 64,75 3 63,68 3 A02BC01 omeprazole 8,62 2 8,85 2 9,29 2 9,94 2 A02BC02 pantoprazole 37,89 4 35,99 4 33,31 5 32,19 5 A02BC03 lansoprazole 5,47 1 5,67 0 5,82 0 6,46 0 A02BC04 rabeprazole 1,59 1 1,48 0 1,37 0 1,27 0 A02BC05 esomeprazole 15,68 2 14,92 2 14,96 2 13,82 2 Page 2 Drug consumption in 2017 - 2020 2020 2019 2018 2017 DDD/ DDD/ DDD/ DDD/ 1000 inhab./ Hospital 1000 inhab./ Hospital 1000 inhab./ Hospital 1000 inhab./ Hospital ATC code Subgroup or chemical substance day % day % day % day % A02BD Combinations for eradication of Helicobacter pylori 0,02 0 0,03 0 0,03 0 0,03 0 A02BD03 lansoprazole, metronidazole and amoxicillin 0,00 0 0,01 0 0,01 0 0,01 0 A02BD07 lansoprazole, amoxicillin and clarithromycin 0,02 0 0,02 0 0,02 0 0,02 0 A02BX Other drugs for peptic ulcer and 1,33 8 1,21 8 1,20 8 1,19 7 gastro-oesophageal reflux disease (GORD) A02BX02 sucralfate 0,35 22 0,29 21 0,26 21 0,25 20 A02BX13 alginic acid 0,98 3 0,91 4 0,94 4 0,95 4 A03 DRUGS FOR FUNCTIONAL 2,67 10 2,74 10 2,72 10 2,80 10 GASTROINTESTINAL DISORDERS A03A DRUGS FOR FUNCTIONAL 1,17 7 1,24 7 1,16 7 1,23 6 GASTROINTESTINAL DISORDERS A03AB Synthetic anticholinergics, quaternary ammonium 0,05 87 0,05 88 0,04 92 0,04 91 compounds A03AB02 glycopyrronium bromide 0,05 87 0,05 88 0,04 92 0,04 91 A03AX Other drugs for functional gastrointestinal disorders 1,12 3 1,18 3 1,12 3 1,18 3 A03AX13 silicones 1,12 3 1,18 3 1,12 3 1,18 3 A03B BELLADONNA AND DERIVATIVES, PLAIN 0,04 93 0,06 95 0,06 94 0,07 81 A03BA Belladonna alkaloids, tertiary amines 0,04 93 0,06 94 0,05 94 0,06 94 A03BA01 atropine 0,04 93 0,06 94 0,05 94 0,06 94 A03BB Belladonna alkaloids semisynthetic, quaternary 0,00 97 0,00 99 0,00 99 0,01 28 ammonium compounds A03BB01 butylscopolamine 0,00 97 0,00 99 0,00 99 0,01 28 A03C ANTISPASMODICS IN COMBINATION WITH 0,18 1 0,21 1 0,20 1 0,24 1 PSYCHOLEPTICS A03CA Synthetic anticholinergic agents in combination 0,18 1 0,21 1 0,20 1 0,24 1 with psycholeptics A03CA02 clidinium and psycholeptics 0,18 1 0,21 1 0,20 1 0,24 1 A03D ANTISPASMODICS IN COMBINATION WITH 0,26 11 0,23 11 0,31 9 0,25 11 ANALGESICS A03DA Synthetic anticholinergic agents in combination 0,26 11 0,23 11 0,31 9 0,25 11 with analgesics A03DA02 pitofenone and analgesics 0,26 11 0,23 11 0,31 9 0,25 11 A03F PROPULSIVES 1,01 11 1,01 11 0,99 11 1,01 11 Page 3 Drug consumption in 2017 - 2020 2020 2019 2018 2017 DDD/ DDD/ DDD/ DDD/ 1000 inhab./ Hospital 1000 inhab./ Hospital 1000 inhab./ Hospital 1000 inhab./ Hospital ATC code Subgroup or chemical substance day % day % day % day % A03FA Propulsives 1,01 11 1,01 11 0,99 11 1,01 11 A03FA01 metoclopramide 1,01 11 1,01 11 0,99 11 1,01 11 A04 ANTIEMETICS AND ANTINAUSEANTS 0,30 43 0,30 45 0,29 45 0,29 48 A04A ANTIEMETICS AND ANTINAUSEANTS 0,30 43 0,30 45 0,29 45 0,29 48 A04AA Serotonin (5HT3) antagonists 0,24 47 0,24 49 0,22 50 0,23 54 A04AA01 ondansetron 0,16 47 0,15 51 0,15 52 0,14 53 A04AA02 granisetron 0,06 43 0,06 40 0,06 40 0,07 48 A04AA05 palonosetron 0,01 100 0,01 100 0,01 100 0,01 100 A04AA55 palonosetron, combinations 0,01 15 0,01 15 0,01 20 0,00 45 A04AD Other antiemetics 0,06 28 0,06 29 0,07 29 0,07 28 A04AD01 scopolamine 0,06 26 0,05 27 0,06 27 0,05 27 A04AD12 aprepitant 0,01 50 0,01 45 0,01 40 0,01 29 A04AD14 rolapitant - - 0,00 53 0,00 66 0,00 92 A05 BILE AND LIVER THERAPY 0,92 3 0,94 3 0,83 2 0,78 2 A05A BILE THERAPY 0,92 3 0,94 3 0,83 2 0,78 2 A05AA Bile acids and derivatives 0,92 3 0,94 3 0,83 2 0,78 2 A05AA02 ursodeoxycholic acid 0,92 3 0,94 3 0,83 2 0,78 2 A05AA04 obeticholic acid 0,00 4 0,00 0 - - - - A06 DRUGS FOR CONSTIPATION 50,33 8 46,99 9 45,74 10 45,61 11 A06A DRUGS FOR CONSTIPATION 50,33 8 46,99 9 45,74 10 45,61 11 A06AB Contact laxatives 6,31 5 6,21 6 6,29 7 6,62 8 A06AB02 bisacodyl 0,71 2 0,91 4 0,97 5 1,08 6 A06AB06 senna glycosides 0,13 0 0,15 0 0,29 0 0,31 1 A06AB08 sodium picosulfate 5,48 6 5,15 7 5,02 8 5,22 9 A06AB58 sodium picosulfate, combinations 0,00 30 0,00 31 0,00 30 0,00 35 A06AC Bulk-forming laxatives 12,01 1 10,77 1 9,96 0 9,84 1 A06AC01 ispaghula (psylla seeds) 11,43 1 10,17 0 9,34 0 9,17 1 A06AC51 ispaghula, combinations 0,59 1 0,61 1 0,62 2 0,66 2 A06AD Osmotically acting laxatives 31,51 11 29,55 12 29,04 13 28,72 14 A06AD11 lactulose 13,23 9 13,46 10 14,18 11 15,02 12 A06AD15 macrogol 17,20 13 14,85 14 13,43 16 11,88 18 A06AD17 sodium phosphate 0,00 - 0,00 - 0,00 - 0,00 - A06AD65 macrogol, combinations 1,08 3 1,24 3 1,43 2 1,83 2 Page 4 Drug consumption in 2017 - 2020 2020 2019 2018 2017 DDD/ DDD/ DDD/ DDD/ 1000 inhab./ Hospital 1000 inhab./ Hospital 1000 inhab./ Hospital 1000 inhab./ Hospital ATC code Subgroup or chemical substance day % day % day % day % A06AG Enemas 0,30 36 0,31 40 0,34 43 0,37 49 A06AG02 bisacodyl 0,24 33 0,25 38 0,28 41 0,30 47 A06AG10 docusate sodium, incl. combinations 0,06 49 0,06 51 0,06 54 0,07 58 A06AH Peripheral opioid receptor antagonists 0,13 28 0,11 33 0,07 39 0,02 48 A06AH01 methylnaltrexone bromide 0,00 97 0,00 95 0,00 93 0,00 96 A06AH03 naloxegol 0,13 26 0,11 31 0,07 36 0,02 36 A06AX Other drugs for constipation 0,06 9 0,04 14 0,04 12 0,04 9 A06AX04 linaclotide 0,03 1 0,02 2 0,02 2 0,02 3 A06AX05 prucalopride 0,02 20 0,02 24 0,02 24 0,01 17 A07 ANTIDIARRHEALS, INTESTINAL 14,08 2 14,06 2 13,86 2 13,88 3 ANTIINFLAMMATORY/ANTIINFECTIVE AGENTS A07A INTESTINAL ANTIINFECTIVES 0,17 21 0,14 25 0,08 28 0,04 34 A07AA Antibiotics 0,17 21 0,14 25 0,08 28 0,04 34 A07AA02 nystatin 0,07 18 0,07 21 0,03 26 0,00 60 A07AA09 vancomycin 0,01 53 0,01 59 0,01 57 0,01 57 A07AA11 rifaximin 0,09 20 0,07 24 0,05 25 0,03 26 A07AA12 fidaxomicin 0,00 73 0,00 78 0,00 77 0,00 87 A07B INTESTINAL ADSORBENTS 0,14 55 0,13 57 0,14 48 0,15 47 A07BA Charcoal preparations 0,14 55 0,13 57 0,14 48 0,15 47 A07BA01 medicinal charcoal 0,14 55 0,13 57 0,14 48 0,15 47 A07C ELECTROLYTES WITH CARBOHYDRATES 0,01 5 0,01 5 0,01 6 0,02 5 A07CA Oral rehydration salt formulations 0,01 5 0,01 5 0,01 6 0,02 5 A07D ANTIPROPULSIVES 1,20 2 1,37 2 1,31 2 1,33 2 A07DA Antipropulsives 1,20 2 1,37 2 1,31 2 1,33 2 A07DA03 loperamide 1,20 2 1,37 2 1,31 2 1,33 2 A07DA06 eluxadoline - - 0,00 0 0,00 1 0,00 1 A07E INTESTINAL ANTIINFLAMMATORY AGENTS 11,75 1 11,22 1 10,83 1 10,56 1 A07EA Corticosteroids acting locally 0,85 3 0,79 3 0,73 3 0,69 3 A07EA02 hydrocortisone - - - - 0,00 0 - - A07EA06 budesonide 0,85 3 0,79 3 0,73 3 0,69 3 A07EB Antiallergic agents, excl.corticosteroids - - - - - - 0,00 1 A07EB01 cromoglicic acid - - - - - - 0,00 1 A07EC Aminosalicylic acid and similar agents 10,90 1 10,43 1 10,10 1 9,86 1 Page 5 Drug consumption in 2017 - 2020 2020 2019 2018 2017 DDD/ DDD/ DDD/ DDD/ 1000 inhab./ Hospital 1000 inhab./ Hospital 1000 inhab./ Hospital 1000 inhab./ Hospital ATC code Subgroup or chemical substance day % day % day % day % A07EC01 sulfasalazine 3,26 1 3,22 1 3,24 1 3,27 1 A07EC02 mesalazine 7,63 1 7,20 1 6,85 1 6,57 1 A07EC03 olsalazine 0,01 3 0,01 1 0,01 1 0,02 1 A07F ANTIDIARRHEAL MICROORGANISMS 0,82 4 1,19 4 1,48 6 1,78 9 A07FA Antidiarrheal microorganisms 0,82 4 1,19 4 1,48 6 0,89 9 A07FA01 lactic acid producing organisms - - 0,00 0 0,05 1 0,07 2 A07FA02 saccharomyces boulardii 0,82 4 1,19 4 1,43 6 1,72 9 A08 ANTIOBESITY PREPARATIONS, EXCL.

View Full Text

Details

  • File Type
    pdf
  • Upload Time
    -
  • Content Languages
    English
  • Upload User
    Anonymous/Not logged-in
  • File Pages
    51 Page
  • File Size
    -

Download

Channel Download Status
Express Download Enable

Copyright

We respect the copyrights and intellectual property rights of all users. All uploaded documents are either original works of the uploader or authorized works of the rightful owners.

  • Not to be reproduced or distributed without explicit permission.
  • Not used for commercial purposes outside of approved use cases.
  • Not used to infringe on the rights of the original creators.
  • If you believe any content infringes your copyright, please contact us immediately.

Support

For help with questions, suggestions, or problems, please contact us